BR0306905A - Vacinas de flavivìrus - Google Patents

Vacinas de flavivìrus

Info

Publication number
BR0306905A
BR0306905A BR0306905-2A BR0306905A BR0306905A BR 0306905 A BR0306905 A BR 0306905A BR 0306905 A BR0306905 A BR 0306905A BR 0306905 A BR0306905 A BR 0306905A
Authority
BR
Brazil
Prior art keywords
flavivirus vaccines
vaccines
flavivirus
manufacturing
methods
Prior art date
Application number
BR0306905-2A
Other languages
English (en)
Other versions
BRPI0306905B8 (pt
BRPI0306905B1 (pt
Inventor
Thomas P Monath
Farshad Guirakhoo
Juan Arroyo
Konstantin Pugachev
Original Assignee
Acambis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29739394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0306905(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acambis Inc filed Critical Acambis Inc
Publication of BR0306905A publication Critical patent/BR0306905A/pt
Publication of BRPI0306905B1 publication Critical patent/BRPI0306905B1/pt
Publication of BRPI0306905B8 publication Critical patent/BRPI0306905B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"VACINAS DE FLAVIVìRUS". A presente invenção refere-se a provê vacinas de flavivírus e métodos de fabricação e uso dessas vacinas.
BRPI0306905A 2002-01-15 2003-01-15 método de produção de uma composição imunogênica/dengue que compreende um flavivírus BRPI0306905B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34894902P 2002-01-15 2002-01-15
US60/348,949 2002-01-15
US38528102P 2002-05-31 2002-05-31
US60/385,281 2002-05-31
PCT/US2003/001214 WO2003103571A2 (en) 2002-01-15 2003-01-15 Flavivirus vaccines

Publications (3)

Publication Number Publication Date
BR0306905A true BR0306905A (pt) 2005-04-12
BRPI0306905B1 BRPI0306905B1 (pt) 2019-05-07
BRPI0306905B8 BRPI0306905B8 (pt) 2021-05-25

Family

ID=29739394

Family Applications (3)

Application Number Title Priority Date Filing Date
BR122018075729A BR122018075729B8 (pt) 2002-01-15 2003-01-15 flavivírus na preparação de uma composição de vacina
BRPI0306905A BRPI0306905B8 (pt) 2002-01-15 2003-01-15 método de produção de uma composição imunogênica/dengue que compreende um flavivírus
BR122018075730-2A BR122018075730B1 (pt) 2002-01-15 2003-01-15 Flavivírus na preparação de uma composição de vacina e composição de vacina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122018075729A BR122018075729B8 (pt) 2002-01-15 2003-01-15 flavivírus na preparação de uma composição de vacina

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122018075730-2A BR122018075730B1 (pt) 2002-01-15 2003-01-15 Flavivírus na preparação de uma composição de vacina e composição de vacina

Country Status (14)

Country Link
US (5) US7459160B2 (pt)
EP (3) EP2295023A1 (pt)
JP (2) JP2005519639A (pt)
KR (2) KR101194818B1 (pt)
CN (1) CN103555669B (pt)
AU (1) AU2003267937C1 (pt)
BR (3) BR122018075729B8 (pt)
CA (1) CA2473321C (pt)
ES (1) ES2924640T3 (pt)
FR (1) FR23C1005I1 (pt)
IL (3) IL163001A (pt)
MX (1) MXPA04006870A (pt)
NZ (1) NZ534159A (pt)
WO (1) WO2003103571A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
PL371187A1 (en) 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
JP2005519639A (ja) * 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
KR101150584B1 (ko) 2002-11-15 2012-06-27 사노피 파스테르 바이오로직스 씨오 웨스트 나일 바이러스 백신
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
WO2006044857A2 (en) 2004-10-20 2006-04-27 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
EP1874346B1 (en) 2005-04-24 2014-06-25 Sanofi Pasteur Biologics, LLC Recombinant flavivirus vaccines
AU2013204985B2 (en) * 2005-04-24 2016-01-28 Sanofi Pasteur Biologics, Llc Recombinant flavivirus vaccines
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
WO2008057550A2 (en) 2006-11-07 2008-05-15 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization
BRPI0909820A2 (pt) 2008-03-05 2015-08-11 Sanofi Pasteur Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
EP2550292B1 (en) * 2010-03-24 2017-11-22 Research Development Foundation Flavivirus host range mutations and uses thereof
WO2012003320A2 (en) 2010-07-01 2012-01-05 Research Development Foundation Flavivirus host-range mutations and uses thereof
MY168959A (en) * 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
CN105246506A (zh) 2013-06-21 2016-01-13 默沙东公司 登革病毒疫苗组合物及其使用方法
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
SG11201704942QA (en) 2014-12-22 2017-07-28 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
US20180229407A1 (en) * 2017-02-03 2018-08-16 Marhaygue, Llc Structural Composition and Method
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
CA3086456A1 (en) 2017-12-21 2019-06-27 Kirin Holdings Kabushiki Kaisha Cross-immunizing antigen vaccine and method for preparation thereof
CN112040954A (zh) 2018-04-27 2020-12-04 雷莫内克斯生物制药有限公司 用于预防或治疗黄病毒感染症的药物组合物
WO2022086300A1 (ko) * 2020-10-23 2022-04-28 에스케이바이오사이언스 주식회사 외래 항원을 코딩하는 유전물질을 포함하는, 타겟 조직의 크기 또는 부피 축소용 백신 조성물 또는 키트
KR20230151488A (ko) * 2022-04-22 2023-11-01 에스케이바이오사이언스(주) 타겟 조직의 크기 또는 부피 축소용 조성물 또는 이를 포함하는 키트

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
ES2153223T3 (es) 1991-09-19 2001-02-16 Us Health Flavivirus quimericos y/o flavivirus de crecimiento restringido.
US6136561A (en) 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6171864B1 (en) * 1996-07-05 2001-01-09 Pioneer Hi-Bred International, Inc. Calreticulin genes and promoter regions and uses thereof
CA2282790C (en) 1997-02-28 2011-04-19 Oravax, Inc. Chimeric flavivirus vaccines
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
DK2295968T3 (da) * 1999-12-03 2012-12-17 Baxter Healthcare Sa Pyrogenicitetsprøve til anvendelse i forbindelse med automatiserede immunanalysesystemer
US7094411B2 (en) 2000-02-16 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
PL371187A1 (en) 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
US6682883B1 (en) 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
MXPA04003692A (es) 2001-10-19 2005-04-08 Acambis Inc Metodos para prevenir y tratar la infeccion por flavivirus en animales.
JP2005519639A (ja) 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
KR101150584B1 (ko) 2002-11-15 2012-06-27 사노피 파스테르 바이오로직스 씨오 웨스트 나일 바이러스 백신
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
WO2005040390A1 (fr) 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. Vaccin recombine utilisant le virus de la fievre jaune comme vecteur
WO2005049815A1 (en) 2003-11-21 2005-06-02 K.U.Leuven Research & Development Flavivirus replication
WO2006044857A2 (en) 2004-10-20 2006-04-27 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
EP1874346B1 (en) 2005-04-24 2014-06-25 Sanofi Pasteur Biologics, LLC Recombinant flavivirus vaccines
BRPI0613328A2 (pt) 2005-06-17 2011-01-04 Sanofi Pasteur cepa do vìrus da dengue-1 vivo atenuado, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada e fragmento de poliproteìna
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
CN203286821U (zh) 2013-05-03 2013-11-13 珠海格力电器股份有限公司 双级增焓空调系统

Also Published As

Publication number Publication date
WO2003103571A3 (en) 2004-04-22
EP1471873A2 (en) 2004-11-03
IL223457A0 (en) 2013-02-03
BRPI0306905B8 (pt) 2021-05-25
ES2924640T3 (es) 2022-10-10
MXPA04006870A (es) 2005-05-16
US8852914B2 (en) 2014-10-07
KR20040078666A (ko) 2004-09-10
IL223458A0 (en) 2013-02-03
JP2005519639A (ja) 2005-07-07
JP5554646B2 (ja) 2014-07-23
IL163001A (en) 2012-12-31
US20150024004A1 (en) 2015-01-22
EP3679915B1 (en) 2022-06-01
US10172929B2 (en) 2019-01-08
KR101074175B1 (ko) 2011-10-14
BR122018075729B1 (pt) 2020-02-11
EP2295023A1 (en) 2011-03-16
CN103555669A (zh) 2014-02-05
KR101194818B1 (ko) 2012-10-25
US7459160B2 (en) 2008-12-02
EP1471873A4 (en) 2005-03-16
KR20110013494A (ko) 2011-02-09
EP3679915A1 (en) 2020-07-15
US20190192649A1 (en) 2019-06-27
CN103555669B (zh) 2017-10-13
JP2010268804A (ja) 2010-12-02
BRPI0306905B1 (pt) 2019-05-07
AU2003267937B2 (en) 2008-09-18
WO2003103571A2 (en) 2003-12-18
NZ534159A (en) 2007-03-30
US20080274142A1 (en) 2008-11-06
US20090191240A1 (en) 2009-07-30
CA2473321C (en) 2015-10-06
BR122018075729B8 (pt) 2021-07-27
US20130189306A1 (en) 2013-07-25
AU2003267937C1 (en) 2019-08-08
BR122018075730B1 (pt) 2022-04-19
FR23C1005I1 (fr) 2023-03-24
IL223457A (en) 2017-07-31
AU2003267937A1 (en) 2003-12-22
CA2473321A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
BR0306905A (pt) Vacinas de flavivìrus
HUP0303996A2 (hu) Vakcinakészítmények
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
CA97146S (en) Eyeglasses
ATE450663T1 (de) Verschleissteil und -anordnung
DE60208385D1 (de) Antineoplasische kombinationspräparate
DE60222056D1 (de) Hebestuhl
NO20034925D0 (no) Cykliske N-aroylaminer
BRPI0414799A (pt) bifenilóxi-ácidos
ITMI20021822A1 (it) Manicotto elastico e procedimento per la fabbricazione di un manicotto elastico
DE50211643D1 (de) s Einspritzventils
NO20031860L (no) Kahalalid F
DE60213718D1 (de) Befestigungsmittel
DE60220625D1 (de) Verbesserungen an Turbomaschineninjektoren
DE60207331D1 (de) Befestigungselement
WO2003092632A3 (en) Cyclic peptide anti-cancer agents and methods
DE50100531D1 (de) Turbomaschine
ATE369137T1 (de) Lyophilisierte formulierung enthaltend olanzapin
CA97145S (en) Eyeglasses
BR0107592A (pt) Compostos calcilìticos
FI20010867A0 (fi) Murskain
DE60131182D1 (de) Höhenmessgerät
ATE343390T1 (de) Kalzilytische verbindungen
DE60112036D1 (de) Uhrwerk

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 15/01/2023